Guided Therapeutics (GTHP) Net Income towards Common Stockholders Growth (1y) (2011 - 2026)
Guided Therapeutics (GTHP) Net Income towards Common Stockholders Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | -47.84% |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 44.34% |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 18.55% |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 13.80% |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | -27.18% |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | 38.54% |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 14.80% |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | 73.85% |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | 12.92% |
| 10 | Guided Therapeutics | 21.24 Mn | 21.23 Mn | - | 29.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.44% |
| Dec 31, 2025 | -70.86% |
| Sep 30, 2025 | -13.44% |
| Jun 30, 2025 | -12.93% |
| Mar 31, 2025 | -4.99% |
| Dec 31, 2024 | -49.25% |
| Sep 30, 2024 | 3.49% |
| Jun 30, 2024 | 52.74% |
| Mar 31, 2024 | 54.49% |
| Dec 31, 2023 | 74.74% |
| Sep 30, 2023 | 31.97% |
| Jun 30, 2023 | -59.29% |
| Mar 31, 2023 | 8.15% |
| Dec 31, 2022 | -264.83% |
| Sep 30, 2022 | -1,966.67% |
| Jun 30, 2022 | 13.11% |
| Mar 31, 2022 | -84.44% |
| Dec 31, 2021 | -124.02% |
| Sep 30, 2021 | -103.34% |
| Jun 30, 2021 | 82.87% |